BioCentury | Aug 2, 2019
Financial News

Aug. 2 Financial Quick Takes: Rakuten Medical bags another $100M; plus CGeneTech, Zecen, Qyuns and more

...Hiroshi Mikitani leading the round. Mikitani is also CEO of Rakuten Medical, formerly known as Aspyrian Therapeutics...
BioCentury | Jan 4, 2019
Financial News

Rakuten Aspyrian grows series C to $284M

...markets cetuximab as Erbitux to treat SCCHN and colorectal cancer. Rakuten Aspyrian Inc., San Diego, Calif. Alicia Parker ASP-1929 (RM-1929) Rakuten Aspyrian Inc. Rakuten...
BioCentury | Dec 22, 2018
Financial News

Rakuten Aspyrian grows series C to $284M

...Lilly and Co. (NYSE:LLY) markets cetuximab as Erbitux to treat SCCHN and colorectal cancer. Alicia Parker ASP-1929 (RM-1929) Rakuten Aspyrian Inc....
BioCentury | Aug 31, 2018
Financial News

Rakuten’s Mikitani leads Aspyrian's $150M series C

...NYSE:LLY) markets cetuximab as Erbitux to treat SCCHN and colorectal cancer. Rakuten Aspyrian Inc., San Diego, Calif. Mark Zipkin RM-1929 Aspyrian Therapeutics...
BioCentury | Aug 23, 2018
Financial News

Rakuten’s Mikitani leads Aspyrian's $150M series C

...Eli Lilly and Co. (NYSE:LLY) markets cetuximab as Erbitux to treat SCCHN and colorectal cancer. Mark Zipkin RM-1929 Aspyrian Therapeutics...
BioCentury | Oct 13, 2016
Translation in Brief

Zapping Tregs

...cetuximab-IR700 conjugate that triggers light-induced killing of cells expressing epidermal growth factor receptor (EGFR) . Aspyrian Therapeutics...
BioCentury | Sep 1, 2016
Distillery Therapeutics

Therapeutics: Interleukin-2 receptor α chain (CD25)

...in Phase I testing for acute myelogenous leukemia (AML), Hodgkin's disease and Non-Hodgkin's lymphoma (NHL). Aspyrian Therapeutics...
BioCentury | Mar 14, 2016
Financial News

Aspyrian Therapeutics completes venture financing

Aspyrian Therapeutics Inc. , San Diego, Calif. Business: Cancer, Antibodies Date completed: 2016-03-10 Type: Venture financing Raised: $40 million Investor: Private investor WIR Staff cancer...
BioCentury | Mar 11, 2016
Financial News

Aspyrian raises $40M in series B round

Aspyrian Therapeutics Inc. (San Diego, Calif.) raised $40 million in a series B round from Hiroshi Mikitani, an Aspyrian director. Mikitani is CEO of Japanese e-commerce company Rakuten Inc. (Tokyo:4755). Aspyrian has an exclusive license...
BioCentury | Aug 3, 2015
Financial News

Aspyrian Therapeutics financial update

Aspyrian Therapeutics Inc. , San Diego, Calif. Business: Cancer, Antibodies Date announced: 2015-07-27 Note: Aspyrian raised $4.3 million in an extension of a series A round, bringing the total raised in the round to $12.7 million....
Items per page:
1 - 10 of 12
BioCentury | Aug 2, 2019
Financial News

Aug. 2 Financial Quick Takes: Rakuten Medical bags another $100M; plus CGeneTech, Zecen, Qyuns and more

...Hiroshi Mikitani leading the round. Mikitani is also CEO of Rakuten Medical, formerly known as Aspyrian Therapeutics...
BioCentury | Jan 4, 2019
Financial News

Rakuten Aspyrian grows series C to $284M

...markets cetuximab as Erbitux to treat SCCHN and colorectal cancer. Rakuten Aspyrian Inc., San Diego, Calif. Alicia Parker ASP-1929 (RM-1929) Rakuten Aspyrian Inc. Rakuten...
BioCentury | Dec 22, 2018
Financial News

Rakuten Aspyrian grows series C to $284M

...Lilly and Co. (NYSE:LLY) markets cetuximab as Erbitux to treat SCCHN and colorectal cancer. Alicia Parker ASP-1929 (RM-1929) Rakuten Aspyrian Inc....
BioCentury | Aug 31, 2018
Financial News

Rakuten’s Mikitani leads Aspyrian's $150M series C

...NYSE:LLY) markets cetuximab as Erbitux to treat SCCHN and colorectal cancer. Rakuten Aspyrian Inc., San Diego, Calif. Mark Zipkin RM-1929 Aspyrian Therapeutics...
BioCentury | Aug 23, 2018
Financial News

Rakuten’s Mikitani leads Aspyrian's $150M series C

...Eli Lilly and Co. (NYSE:LLY) markets cetuximab as Erbitux to treat SCCHN and colorectal cancer. Mark Zipkin RM-1929 Aspyrian Therapeutics...
BioCentury | Oct 13, 2016
Translation in Brief

Zapping Tregs

...cetuximab-IR700 conjugate that triggers light-induced killing of cells expressing epidermal growth factor receptor (EGFR) . Aspyrian Therapeutics...
BioCentury | Sep 1, 2016
Distillery Therapeutics

Therapeutics: Interleukin-2 receptor α chain (CD25)

...in Phase I testing for acute myelogenous leukemia (AML), Hodgkin's disease and Non-Hodgkin's lymphoma (NHL). Aspyrian Therapeutics...
BioCentury | Mar 14, 2016
Financial News

Aspyrian Therapeutics completes venture financing

Aspyrian Therapeutics Inc. , San Diego, Calif. Business: Cancer, Antibodies Date completed: 2016-03-10 Type: Venture financing Raised: $40 million Investor: Private investor WIR Staff cancer...
BioCentury | Mar 11, 2016
Financial News

Aspyrian raises $40M in series B round

Aspyrian Therapeutics Inc. (San Diego, Calif.) raised $40 million in a series B round from Hiroshi Mikitani, an Aspyrian director. Mikitani is CEO of Japanese e-commerce company Rakuten Inc. (Tokyo:4755). Aspyrian has an exclusive license...
BioCentury | Aug 3, 2015
Financial News

Aspyrian Therapeutics financial update

Aspyrian Therapeutics Inc. , San Diego, Calif. Business: Cancer, Antibodies Date announced: 2015-07-27 Note: Aspyrian raised $4.3 million in an extension of a series A round, bringing the total raised in the round to $12.7 million....
Items per page:
1 - 10 of 12